Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
m Updated table
No edit summary
 
(18 intermediate revisions by 4 users not shown)
Line 293: Line 293:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Line 338: Line 338:
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|PENDING
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 370: Line 370:
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|PENDING
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|JH_MS
|JH_MS
Line 386: Line 386:
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 406: Line 406:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 419: Line 419:
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|PENDING
|Gordana Raca MD PhD,
|
|9/8/25
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 438: Line 438:
|12/20/23
|12/20/23
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 451: Line 451:
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|Open to new author
|
|
|
|
|
Line 458: Line 458:
|JH_MS
|JH_MS
|
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
Line 467: Line 470:
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 483: Line 486:
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 490: Line 493:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
Line 522: Line 525:
|JH_MS
|JH_MS
|
|
|
|Prior author: Celeste Eno, PhD
 
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
Line 547: Line 552:
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|PENDING
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 563: Line 568:
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|PENDING
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 582: Line 587:
|5/1/24
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 595: Line 600:
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 602: Line 607:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 611: Line 616:
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 618: Line 623:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 630: Line 635:
|5/1/24
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 643: Line 648:
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 650: Line 655:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 662: Line 667:
|6/11/24
|6/11/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 698: Line 703:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 727: Line 732:
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|PENDING
|Malini Sathanoori, Ph.D.
|
|12/6/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 743: Line 748:
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 750: Line 755:
|JH_MS
|JH_MS
|
|
|
|Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
Line 858: Line 864:
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|Rolando Garcia
|2/7/2025
|
|
|
|Pending
|
|
|
|
|FQR
|FQR
Line 942: Line 948:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 962: Line 968:
|JH_MS
|JH_MS
|
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
Line 974: Line 980:
|5/9/24
|5/9/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 1,007: Line 1,013:
|7/1/24
|7/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 1,067: Line 1,073:
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|PENDING
|Daynna Wolff
|
|5/3/2025
|
|8/3/2025
|
|Pending
|
|
|GC
|GC
Line 1,099: Line 1,105:
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,110: Line 1,116:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,126: Line 1,132:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
Line 1,147: Line 1,153:
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025
|
|Pending
|
|
|GC
|GC
Line 1,165: Line 1,171:
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|Pending
|
|
Line 1,181: Line 1,187:
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|Pending
|
|
Line 1,197: Line 1,203:
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|Pending
|
|
Line 1,227: Line 1,233:
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,239: Line 1,245:
|Complete
|Complete
|10/01/2021
|10/01/2021
|Date completed by author: 10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
|-
!Disease (5th Edition)
!Disease (5th Edition)
Line 1,290: Line 1,296:
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,306: Line 1,312:
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,354: Line 1,360:
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,365: Line 1,371:
|Sudha Arumugam, MD
|Sudha Arumugam, MD
|Complete
|Complete
|01/24/2022
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|Date completed by author: 01/24/2022
|-
|-
Line 1,644: Line 1,650:
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| || || || ||Shivani Golem (SG)
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
| ||
|Monoclonal B-cell Lymphocytosis
|Monoclonal B-cell Lymphocytosis
Line 1,665: Line 1,671:
|-
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
|7/16/24|| ||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,672: Line 1,678:
|
|
|-
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,706: Line 1,712:
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|Disease
|PENDING
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
Line 1,722: Line 1,728:
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|Disease
|PENDING
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
Line 1,740: Line 1,746:
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Disease
|Pending
|Molly Walkenhorst
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
Line 1,772: Line 1,778:
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Disease
|PENDING
|Andrew Ly
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
Line 1,788: Line 1,794:
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,806: Line 1,812:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,822: Line 1,828:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,836: Line 1,842:
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Disease
|PENDING
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
Line 1,854: Line 1,860:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|Pending
|
|
Line 1,868: Line 1,874:
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Disease
|PENDING
|Linlin Gao
|
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
Line 1,884: Line 1,890:
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Line 1,902: Line 1,908:
|PENDING
|PENDING
|
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
Line 1,916: Line 1,922:
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Disease
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,925: Line 1,931:
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,948: Line 1,954:
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Disease
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,957: Line 1,963:
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
Line 1,977: Line 1,983:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
| || || || ||GC|| ||
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,985: Line 1,991:
|
|
|-
|-
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Pending
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Afia Hasnain, MBBS, PhD
|Complete
|Complete
|5/26/2021
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|-
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|Burkitt-Like Lymphoma with 11q Aberration
|Burkitt-Like Lymphoma with 11q Aberration
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Comlete
|Complete
|27/01/2022
|27/01/2022 Emailed 5/7//2025, no reply
|
|
|-
|-
Line 2,047: Line 2,053:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
Line 2,062: Line 2,068:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Plasmablastic Lymphoma
Line 2,070: Line 2,076:
|
|
|-
|-
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
| || || || ||GC|| ||
|6/28/2025
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
Line 2,085: Line 2,092:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
| || || || ||GC|| ||
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
Line 2,107: Line 2,116:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|Complete
|16/11/2021
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|Complete
|28/06/2021
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
Line 2,197: Line 2,206:
|
|
|-
|-
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
| || || ||
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
Line 2,206: Line 2,216:
|
|
|-
|-
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,267: Line 2,279:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
| || || || ||SG
| || || || ||SG
| ||
| ||
Line 2,276: Line 2,288:
|
|
|-
|-
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
| || || || ||SG
| || || || ||SG
| ||
| ||
Line 2,293: Line 2,305:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
| || || || ||SG
| || || || ||SG
| ||
| ||
Line 2,310: Line 2,322:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
| || || ||
|SG
|SG
Line 2,336: Line 2,348:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang
| || || || ||SG
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
Line 2,346: Line 2,360:
|-
|-
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| || || ||
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
|SG
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
Line 2,873: Line 2,888:
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|Disease
|PENDING
|
|
|
|
|
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"